

[Amphotericin B](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.3. Antifungal medicines](#)

ATC codes: [J02AA01](#)

EMLc

Indication

Candidosis ICD11 code: [1F23.Z](#)

INN

Amphotericin B

Medicine type

Chemical agent

List type

Core

Additional notes

*Liposomal amphotericin B has a better safety profile than the sodium deoxycholate formulation and should be prioritized for selection and use depending on local availability and cost.

Formulations

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex) ; 50 mg in vial powder for injection (as sodium deoxycholate)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1984 ([TRS 722](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2009 ([TRS 958](#))

Changed in 2013 ([TRS 985](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Amphotericin B](#)

DrugBank

[Amphotericin b](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.